Market Drivers

  • Launch of nine novel immunotherapies (four immune checkpoint inhibitors and ve therapeutic vaccines) across ve indications: malignant melanoma, non-small-cell lung cancer (NSCLC), renal cell carcinoma, prostate cancer, and glioblastoma multiforme.
  • Expected premium price of emerging immunotherapies and potential long treatment durations with agents that target the anti-programmed cell death-1/programmed death-ligand-1 (PD-1/PD-L1) pathway.
  • Potential for combination approaches, including dual blockade of the immune checkpoint pathway, of immune checkpoint inhibitors and therapeutic vaccines, and of immunotherapies with agents belonging to other drug classes.
  • Potential use of PD-L1 expression as a predictive biomarker for identifying which patients will most likely bene t from emerging anti-PD-1/PD-L1 agents in NSCLC.

DRG becomes Clarivate

View Now